Polyplus-transfection, a leading biotechnology company that supports the gene and cell therapy market by supplying innovative transfection solutions, named Mario Philips as Chief Executive Officer. He succeeds Karsten Wilking, who will transition into a strategic advisor role. Prior to this appointment, Mario Philips served as CEO of French biotech company Polyneuros, a developer of kits for the diagnosis and treatment of neurodegenerative conditions including Parkinson’s disease and amyotrophic lateral sclerosis. Mario was also a strategic partner with ArchiMed where he contributed his deep experience of the bioprocessing sector. Previously, he served as VP and General Manager of Pall Biotech, where he had full P&L responsibilities for the Biotechbusiness unit within NYSE-listed Danaher and led the rapid expansion of the group’s core bioprocessing capabilities. Prior to Pall Biotech, Mr. Philips served as SVP and General Manager of ATMI Life Sciences, where he led the introduction of new products and service solutions for the Life Sciences industry including the iCELLis™ single-use bioreactor, a leading bioreactor technology for gene therapy applications.In addition, Polyplus has named Dr. Andreas Rummelt and Jean-Paul Mangeolle to its board of directors. Dr. Andreas Rummelt is currently the CEO and partner of InterPharmaLink AG, a management consulting firm focused on advising companies in the healthcare industry. Dr. Rummelt was Group Head of Quality Assurance and Technical Operations at Novartis and served as a member of the executive committee there. He also held various positions of increasing responsibility in development for Sandoz Pharma Ltd including CEO, Head of Worldwide Technical Research and Development, and Head of Technical Operations of the Novartis Pharmaceuticals Division. In addition to Polyplus, Dr. Rummelt is a member of the board of directors of Alexion Pharmaceuticals, Xellia Pharmaceuticals, and Alvogen, in addition to several international advisory boards.
Jean-Paul Mangeolle has more than 35 years of experience as a global biotechnology executive. He served as President of the SCIEX Group, a unit of Danaher. Prior to SCIEX Group, he was an Executive Vice President with Merck KGaA responsible for the process solutions division and previously held executive positions with Millipore Corporation. In addition to Polyplus, Mr. Mangeolle currently serves on the boards of directors of Charles River Labs, Gelest, and TeraPore Technologies and is a co-founder of Petri Bio, an early stage venture capital firm.
COMMENTS ARE OFF THIS POST